Structural Heart Disease

Latest analysis of the HELIOS-B trial finds vutrisiran significantly lowers mortality and cardiovascular events in patients with ATTR-CM.

Our April 2025 month in review highlights breakthroughs in gene therapy, device innovations, and evolving treatment strategies for cardiology.

Researchers indicated an association between the index and 365-day mortality.

Le discusses his anticipation for the results of upcoming cardiology trials in 2025, including HORIZON and Target-D.

Our Q1 2025 recap for cardiology spotlights 6 regulatory updates, 5 key trial announcements, and top expert perspectives in cardiac care.

Marc Bonaca, MD, MPH, examines the benefit of semaglutide on functional outcomes in PAD from the STRIDE trial at ACC.25.

Le examines the STRIDE, SOUL, and DapaTAVI trials presented at this year’s ACC Scientific Sessions.

Dapagliflozin lowered the incidence of all-cause death or worsening of heart failure versus standard care in the DapaTAVI trial at ACC.25.

The IND submission for VERVE-102 was supported by interim data from the dose-escalation portion of the ongoing Heart-2 Phase 1b clinical trial.

Bhatt previews 3 late-breaking clinical trials being presented at this year's American College of Cardiology Annual Scientific Sessions.

The regulatory agency accepted the BLA's filing and assigned a target action date of August 31, 2025.

Our top 5 headlines include 5 key FDA decisions, including the first approval for stroke in 3 decades, an expanded indication for pediatric anaphylaxis, and more!

The agency approved the first generic of the anticoagulant rivaroxaban to lower the risk of cardiovascular and thromboembolic events in adults with CAD and PAD.

Mehrdad Ghoreishi, MD explores the latest advances in aortic disease treatment and the role of minimally invasive techniques.

The American Heart Association’s 2025 statistical update confirms cardiovascular diseases claim more US lives than all forms of cancer and accidental deaths.

Only 7% of patients presenting to US emergency departments received cardiac biomarker testing, with 2.8% diagnosed with ACS.

Medicaid-insured heart transplant recipients reported worse survival and higher risk of cardiac allograft vasculopathy over 5 years.

Nearly half of patients with acute coronary syndrome in a single-center analysis exhibited iron deficiency, with anemia linked to a greater impact on mortality.

Greg Duck, PA-C shared insights from his CAPP 2024 presentation on tailoring medical management and effective treatment of methamphetamine-induced cardiomyopathy.

Bob Ross, PA-C, shares expert insights on early PAD detection, updated guidelines, and practical tools to improve vascular health outcomes from CAPP 2024.

The FDA set the Prescription Drug User Fee Act (PDUFA) date for the investigational RNAi therapeutic as March 23, 2025.

Birgit Vogel, MD discusses racial inequities and geographic variations in peripheral artery disease care in the United States.

Milind Desai, MD describes favorable real-world safety outcomes from mavacamten use over 22 months of the Risk Evaluation and Mitigation Strategy (REMS) program.

Marianna Fontana, MD, PhD discusses Phase 1 interim results on the CRISPR-based gene-editing therapy, nex-z, for ATTR-CM.

Marianna Fontana, MD, PhD describes the prognostic importance of a decline in eGFR in a retrospective cohort of patients with ATTR-CM.